^
BIOMARKER:
Chr t(11;14)
Chr t(11;14)
Multiple Myeloma
VenVd
Sensitive
:
A2
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib
Sensitive
:
B
Chr t(11;14)
Multiple Myeloma
venetoclax + carfilzomib
Sensitive
:
C2
Chr t(11;14)
Multiple Myeloma
VRD
Resistant
:
C3
Chr t(11;14)
Multiple Myeloma
bortezomib
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
BRAF inhibitor + MEK inhibitor
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
BRAF inhibitor
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
venetoclax
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
venetoclax + atezolizumab + cobimetinib
Sensitive
:
C3
Chr t(11;14)
Multiple Myeloma
venetoclax + cobimetinib
Sensitive
:
C3
Chr t(11;14)
Leukemia
DOT1L inhibitor + venetoclax
Sensitive
:
D
Chr t(11;14)
Multiple Myeloma
APG-2575
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our